Oct 5, 2026 | Press Releases
Jensen, who as CEO led Nasdaq-listed biotech Allarity Therapeutics’ refocusing around a single lead asset, cites Valion’s rare combination of government funding, FDA designations, human safety data and wholly owned U.S. manufacturing SAN ANTONIO, TX /...
Sep 30, 2026 | Press Releases
Needle-free program creates a potential second development pathway alongside Valion’s injectable Entolimod programNext study will test whether the formulation delivers measurable amounts of Entolimod into the bloodstream SAN ANTONIO, TX / ACCESS Newswire /...
Sep 23, 2026 | Press Releases
Leadership changes strengthen alignment and execution as Company advances Entolimod and evaluates strategic, commercial and government opportunities SAN ANTONIO, TX / ACCESS Newswire / September 23, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) (“Valion” or the...
Sep 22, 2026 | Press Releases
Nasdaq confirms compliance with continued listing standard and closes the matter SAN ANTONIO, TX / ACCESS Newswire / September 22, 2026 / Valion Bio, Inc. (Nasdaq:VBIO) (“Valion” or the “Company) announced today that it has received formal written...
Sep 1, 2026 | Press Releases
Current CFO, Lisa Wolf named President and COO, assuming expanded executive and operational leadership. Jared Malbin and Thomas Jensen appointed as directors.Lead Asset Positioned for Significant Markets: Entolimod targets the projected $7.8 billion Acute Radiation...